SG Americas Securities
NBIX icon

SG Americas Securities’s Neurocrine Biosciences NBIX Stock Holding History

SG Americas Securities’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20,000
Closed -$21K – 3451
2022
Q4 		$21K Buy
+20,000
New +$2.34M ﹤0.01% 2930
2020
Q2 		– Sell
-79,000
Closed -$276K – 3797
2020
Q1 		$276K Buy
+79,000
New +$7.73M ﹤0.01% 2295

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SG Americas Securities's NBIX Position: Q2 2026 in Review

SG Americas Securities increased its Neurocrine Biosciences (NBIX) stake by 139% in Q2 2026, buying an estimated $12.2M and bringing the position to 141,613 shares worth $23.9M. The position accounts for 0.01% of the portfolio, ranked #548.

SG Americas Securities first reported a position in NBIX in Q2 2013 and has held it in 43 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • SG Americas Securities held 141,613 shares of Neurocrine Biosciences worth $23.9M as of Q2 2026.
  • SG Americas Securities bought 82,346 Neurocrine Biosciences shares in Q2 2026, an estimated $12.2M.
  • Neurocrine Biosciences made up 0.01% of SG Americas Securities's portfolio in Q2 2026, its #548 holding.
  • SG Americas Securities first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 43 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.